Abbvie will acquire Gilgamesh's novel MDD investigational drug bretisilocin
On August 26th, Abbvie announced a definitive agreement to acquire a research candidate drug, a 5-HT2A receptor agonist and 5-HT releasing agent bretisilocin, from Gilgamesh Pharmaceuticals for the treatment of moderate to severe depression
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments